chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Feel a little fussy; A lot of pain in my left arm to my shoulder and fingers; Vomit, vomited for about 20 minutes; Nausea; Headache; This spontaneous case was reported by a consumer and describes the occurrence of IRRITABILITY (Feel a little fussy), PAIN IN EXTREMITY (A lot of pain in my left arm to my shoulder and fingers), VOMITING (Vomit, vomited for about 20 minutes), NAUSEA (Nausea) and HEADACHE (Headache) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure. Concomitant products included ALUMINIUM HYDROXIDE, MAGNESIUM HYDROXIDE, SIMETICONE (PEPSID), VENLAFAXINE HYDROCHLORIDE (EFFEXOR), ACETYLSALICYLIC ACID (BABY ASPIRIN), VITAMIN B NOS and COLECALCIFEROL (D) for an unknown indication.   On 04-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, the patient experienced IRRITABILITY (Feel a little fussy), PAIN IN EXTREMITY (A lot of pain in my left arm to my shoulder and fingers), VOMITING (Vomit, vomited for about 20 minutes), NAUSEA (Nausea) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) for Headache, at an unspecified dose and frequency. On 04-Feb-2021, IRRITABILITY (Feel a little fussy), VOMITING (Vomit, vomited for about 20 minutes) and NAUSEA (Nausea) had resolved. On 07-Feb-2021, PAIN IN EXTREMITY (A lot of pain in my left arm to my shoulder and fingers) and HEADACHE (Headache) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Feb-2021, Blood pressure measurement: elevated (High) Elevated.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the drug in response to the events was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 25-May-2021: Follow-up information received on 25-MAY-2021 contains non-significant information (Contact information updated).
pt recv vax 5MAY95 & 13MAY95 pt devel chicken pox; f/u info recv from the pts MD stated pt devel approx 100 vesicles all over body; no itching, fever or other sx;
no adverse effect reported; 26 year old patient received one dose of PROQUAD; This spontaneous report has been received from a medical assistant referring to a 26-year-old patient of unknown gender. No information was provided regarding the patient's pertinent medical history, concomitant medication and drug reactions/allergies.   On 27-AUG-2019, the 26-year-old patient was vaccinated with one dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD), via subcutaneous route for prophylaxis (Therapy type: rHA, Lot # S006830, expiry date: 02-SEP-2020). Other suspect therapies included sterile diluent (Lot # S013899, expiry date: 07-MAR-2022) (Inappropriate age at vaccine administration). No adverse effect reported. It was unknown if the patient received treatment for the event. It was unknown whether laboratory diagnostics were performed.  This is one of the two report received from the same reporter.; Sender's Comments:  US-009507513-1908USA012364:
Nausea; arm pain; REDNESS; HEADACHE; MUSCLE ACHE; This case was reported by a consumer and described the occurrence of nausea in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 12th October 2021, the patient received the 1st dose of Shingrix. On an unknown date, less than 4 months after receiving Shingrix, the patient experienced nausea, pain in arm, erythema, headache and muscle pain. On an unknown date, the outcome of the nausea, pain in arm, erythema, headache and muscle pain were recovered/resolved.   It was unknown if the reporter considered the nausea, pain in arm, erythema, headache and muscle pain to be related to Shingrix.     Linked case(s) involving the same patient:  US2022AMR060153, US2022AMR060910   Additional Information: GSK receipt date:06-Apr-2022 Reporter's comment: The patient received a dose of Shingrix in left arm. The patient stated that side effects from the Shingrix vaccine were rough compared to the other vaccines. The events lasted for about 2.5 days. The reporter gave consent to follow-up with health care professional (pharmacy). Additional Supportive Information: For tolerance of 2nd and 3rd dose, refer US2022AMR060910 and US2022AMR060153, respectively.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR060153:same reporter US-GLAXOSMITHKLINE-US2022AMR060910:same reporter
Hep A vaccine administered in (R) delt, Tdap administered in (L) delt. Pt was sitting during injections and remained sitting after injections. Approx. 3-5 minutes after injections pt became pale, dizzy and proceeded to pass out. Pt awoke after approximately 30 sec. Pt's (R) arm and (R) leg made jerking motions while pt was passed out. Pt then woke up was alert and oriented. Laid down for approximately 5 minutes, then drank apple juice and sat up approximately 10 minutes. Pt then felt he was recovered completely.
This spontaneous report was received from a licensed practical nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided. On an unknown date, the patient was vaccinated with improperly stored GARDASIL 9 (strength, dose and route were not reported) (lot # N023828 and expiration date: 25-JUN-2020) for prophylaxis (product storage error). The vaccine was stored in below 32 degrees Fahrenheit (F) / 0 degree Celsius (C) (-0.3 C) for 64 hours. The digital data logger was not involved in recording the temperature excursion. No adverse effects were reported. There was no product quality complaint (PQC) reported. This is one of the several reports received from same reporter. Sender's Comments: US-009507513-1806USA012211: US-009507513-1806USA012212: US-009507513-1806USA012213.
Physician reported pediatric patient received adult dose of VAQTA.; Physician reported pediatric patient received adult dose of VAQTA.; No Adverse Event; This spontaneous report was received from a physician refers to a patient of unknown age (reported as: pediatric patient) and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 13-JUN-2023, the patient was vaccinated with adult dose of hepatitis a vaccine, inactivated (VAQTA) lot #W017819, expiration date: 27-DEC-2023 (exact dose, route of administration and anatomical location were not reported) for prophylaxis.   It was reported that, the pediatric patient received adult dose of hepatitis a vaccine, inactivated (VAQTA) on 13-JUN-2023 (product administered to patient of inappropriate age, incorrect dose administered). No additional adverse event (no adverse event).
After the vaccine administration, when patient was about to go to the area of observation, she reports feeling dizzy and unable to get up. She reports her arm fell asleep.
Redness and swelling to left deltoid 1 day after receiving Dtap vaccine. Temp 104. Cellulitis diagnosed by hospital physician. Antibiotics prescribed.  Redness and swelling still visible 2 days after vaccination but mother reports improvement.
Myalgia, Fever, chills flu like symptoms, eyes watering Narrative: Treated with OTC tylenol.  Other Relevant History:
pt recv vax 31OCT96 & the day of vax pt exp redness & warmth @ the site of vax;4OCT96 pt exp fever, h/a, disorientation & dizziness which persisted for 3 days;exp lt sided back pain & arthralgia;pt stated had diff walking d/t arthralgia;
11 month old received 1st set of vaccines 9/3/2008. Dtap-HIB-IPV, Prevnar, Act HIB.; Child developed hives on back of neck and legs. No fever. Child was irritable. Approximately 24 hours later. Hives continue to come and go. Appt with Dr today. 9/8/08
feverish (101.8), sore throat, dizzy, thick brown/yellow mucous, back pain;
The patient became very dizzy and lightheaded, sweaty. I got her some water and had her lie on her back. She said that really helped. After 5 minutes, she sat in the chair again and had some more water. After 10 more minutes, she was feeling much improved. I had her wait 15 more minutes before leaving the pharmacy. The patient left feeling normal again.
Pt described light headedness and dizziness, b/p 203/75.  Pt was given Clonidine 0.1mg tab
Patient arrive to vaccination site to get the influenza vaccine. Patient properly screened for influenza but got a Covid Vaccine instead. Pt already had her two vaccines in Jul and Aug.
17 days post vax, pt developed a generalized varicella-like rash, consisting of approximately 50 lesions. Unspecified medical attention was sought and subsequently, the rash resolved. It was reported that the pt came in contact with 2 pregnant women in their 3rd trimester. Additional information has been requested.
Left arm pain 6 cm fever, erythema, stiffening above the elbow appearing several days after TDaP injection.  Also rash upper chest area 4 days after injection.
After I received the vaccine, after I went upstairs to go back to work (about 30 min later) I felt my hands and feet very cold and numb. I also felt dizzy and my hands and feet kept cold. Kept trying water and coke and I was continuously dizzy, a weird dizzy, like I had taken some kind of drug. My coworkers said I had slurred speech, my BP was 180/120 and my heart rate was 140. They sent me down to the ER. As soon as I laid down at the ER I started feeling better and within one hour my symptoms were gone. I also felt very sleepy throughout, as soon as I started feeling dizzy. I was fighting the sleep.
Excessive fatigue and nosebleeds, headaches, some nausea sleeping more than 13 hours straight through, several times per wk. Sometimes sleeping more than 20 hrs. straight through.
Alopecia areata; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA AREATA (Alopecia areata) and FATIGUE (Fatigue) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Hidradenitis suppurativa.    Concurrent medical conditions included Hidradenitis suppurativa.   On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced ALOPECIA AREATA (Alopecia areata) and FATIGUE (Fatigue). At the time of the report, ALOPECIA AREATA (Alopecia areata) and FATIGUE (Fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications was reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The reporter's causality for the event's of alopecia areata and fatigue was not provided for Skyrizi. No treatment drug details was reported.
Began with tiredness, long nap, followed by fever and headache. The fever, bad headache, and eye ache continued until 1/24/2017, when she broke out in a rash starting on her face. The rash eventually spread to her neck, truck, arms, and legs on 1/25/2017.
I26.94 MULTIPLE SUBSEGMENTAL PULMONARY EMBOLI WITHOUT ACUTE COR PULMONALE 12/10/2022 LACTIC ACIDOSIS, UNSPECIFIED I26.99 ACUTE PULMONARY EMBOLISM 12/10/2022 LACTIC ACIDOSIS, UNSPECIFIED J96.00 ACUTE RESPIRATORY FAILURE 12/29/2022 LACTIC ACIDOSIS, UNSPECIFIED I26.94 MULTIPLE SUBSEGMENTAL PULMONARY EMBOLI WITHOUT ACUTE COR PULMONALE 12/10/2022 LEFT HIP OSTEOPOROTIC FX, INIT I26.99 ACUTE PULMONARY EMBOLISM 12/10/2022 LEFT HIP OSTEOPOROTIC FX, INIT J96.00 ACUTE RESPIRATORY FAILURE 12/29/2022 LEFT HIP OSTEOPOROTIC FX, INIT I26.94 MULTIPLE SUBSEGMENTAL PULMONARY EMBOLI WITHOUT ACUTE COR PULMONALE 12/10/2022 ATRIAL FIBRILLATION W RAPID VENTRICULAR RESPONSE I26.99 ACUTE PULMONARY EMBOLISM 12/10/2022 ATRIAL FIBRILLATION W RAPID VENTRICULAR RESPONSE J96.00 ACUTE RESPIRATORY FAILURE 12/29/2022 ATRIAL FIBRILLATION W RAPID VENTRICULAR RESPONSE
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2 (PFIZER BIONTECH COVID-19 VACCINE), on 05Feb2021 as dose 1, single (Lot number: EL9267), in right arm, on 10Mar2021 as dose 2, single (Lot number: EN603), in right arm and on 01Nov2021 as dose 3 (booster), single (Lot number: FH8020) at the age of 70 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "multiple meningiomas" (unspecified if ongoing); "Arthritis" (unspecified if ongoing); "Eczema" (unspecified if ongoing). No known allergies. Concomitant medications included: BUPROPION HCL; PREGABALIN; CITALOPRAM; THYROXINE; HYDROCORTISONE; MEMANTINE; CELECOXIB; METFORMIN. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jul2022, outcome "recovering" and all described as "COVID 19 Treatment". Clinical course: Patient had sneezing, sore throat, congestion, diarrhea and fatigue, tested positive and started Paxlovid days after the onset of symptoms. After 10 days she was feeling better and tested negative. Her symptoms returned a couple of days later and she tested positive again. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jul2022) Positive; (Jul2022) Negative, notes: After 10 days; (29Jul2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19 and included treatment with Paxlovid.
Injection site: swollen, red welt, itchy, warm to touch -Lasted 3 days, felt better for 2 days then the same symptoms began again for 2 days
After giving the patient his Covid Vaccine, he tensed up and said he was feeling like he may vomit. He then became very pale and fainted while in the vaccination chair. After a few seconds he regained consciousness. We then helped him to the floor and elevated his legs and placed a cold pack on his neck. He started feeling better instantly but we kept him there for about 5 minutes. We then had him move to a chair and the technician sat with him for an additional 40 minutes. He then said he was fine and that he has fainted before (which was not disclosed) and left.
Patient complains 1 week after shot she experienced shooting pain and numbness to her fingers starting at the muscle radiating to the fingers. She reports it is getting a bit better.
High fever since Saturday August 7. Seen in ER 8/12/2004 at 3AM for temp 104 with noted chicken pox rash to trunk. Seen in office 8/12/2004 at 10:30.
No adverse event; adults received 0.5 ml of Moderna vial intended for ages 6-11; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (adults received 0.5 ml of Moderna vial intended for ages 6-11) and NO ADVERSE EVENT (No adverse event) in a 97-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 064A22A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Sep-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 27-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (adults received 0.5 ml of Moderna vial intended for ages 6-11). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (adults received 0.5 ml of Moderna vial intended for ages 6-11) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (adults received 0.5 ml of Moderna vial intended for ages 6-11).    No concomitant medications were reported. No treatment medications were reported.
80 years old female who has past medical history significant for history of advanced dementia, COVID-19 infection and afterwards has declined significantly, completely confused most of the days, significantly lethargic and was sent to the hospital where she was noted to have significant hypernatremia and also acute kidney injury and was recommended admission.  Patient is however unable to give any further details of the history and daughter does not know exactly the details of her last few days of history.  Patient is completely confused and demented and unable to give any review of system  Vitals & Measurements (Last Charted)  T: 97.9 °F(Oral)  TMIN: 96.5 °F(Oral)  TMAX: 97.9 °F(Oral)  HR: 68  RR: 11  BP: 129/69  SpO2: 98%  WT: 43.6 kg  BMI: 18.15
The patient received two shots of the moderna vaccine  01/2021, 02/2021. On 8/26/21, the patient received a booster dose of pfizer
Information has been received from a registered nurse concerning a 69 year old female who was vaccinated with Pneumovax 23 1.0 ml dose instead of 0.5 ml dose.  Subsequently the patient experienced mild local reaction with redness and pain.  Additional information has been requested.
Child received Varicella at 0830 am on 2/14/23. On 2/15/23 at 3 pm, child was observed to have swelling and redness at the injection site. Child brought to after hours Care Clinic for evaluation. There was a 9 cm x 14 cm at the widest areas, of cellulitis present. Area was warm to touch and blanched with pressure. Patient had full ROM of leg. There was a palpable "knot" at the injection site, most likely related to the vaccine with little concern for abscess. Child was afebrile in clinic and per mom afebrile at home. No other changes in the child's health as child was playful, happy and eating her regular diet. Child was prescribed Clindamycin 75mg/5 ml, take 5 ml three times daily for ten days. Discussed with mom need for follow up with PCP vs immediate evaluation in emergency room.
Child was immunized on 12/1/00. Fever started on 12/2/00 at 102.8F followed by diarrhea. On 12/4/00, child broke out in a raised, red rash all over his body. Encouraged mom to take child to PMD for evaluation. On 12/7/00, spoke with parent and stated child was taken to ER and dx'd with Roseola. On 2/9/01, spoke with child's father at work who states the child has completely recovered, has no rash or other problems from this reported incident.
Injection was given on upper arm near shoulder not in muscle on arm.  Pain in arm-, expected. The next night had pain in breast, neck and body. Today when I woke up my glands in my neck were swollen and pain radiates to back and neck. Had no reaction to first two doses of Moderna. Wondering if placement of injection had anything to do with swelling.
Patient presented to Emergency room 5/2/07 with continous vomiting patient transfered to hosital with Malrotation mid gut volvulus and had surgical repair on 5/3/07, had recieved vaccines including rotavirus on 4/26/07.  5/22/07 Received hospital medical records which reveal patient admitted 5/3-5/9/07 after experienced 3 days projectile bilious vomiting FINAL DX: malrotation midgut volvulus & release of LADD bands.
Red blotches, swollen, excruciating pain, limited flexion. Received on 9/28/2011 at 920 am both Influenza and pneumonia shots with lot numbers 691AA and 0813AA respectively on the same location - Right upper arm (RUA). Had pains in my shoulder since then. Recently had surgery at hospital.
Only time my mom had flu is when she got the flu; Initial information regarding an unsolicited valid non-serious social media case was received from a non-healthcare professional (consumer) on 19-Nov-2020.  This case involved an unknown age female patient who only time had flu when she got the flu shot (Influenza), after receiving INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by an unknown manufacturer (lot number and expiry date were not reported) via an unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date (unknown latency), the patient developed only time flu was when the patient got the flu shot (Influenza).  No relevant laboratory details were provided.  It was not reported if the patient received a corrective treatment.  Outcome of the event of influenza was unknown.  There will be no information available on the batch number for this case.
patient wanted to receive second dose of primary series 6 months after first dose; No adverse event; This spontaneous case was reported by a physician and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (patient wanted to receive second dose of primary series 6 months after first dose) and NO ADVERSE EVENT (No adverse event) in a 24-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (patient wanted to receive second dose of primary series 6 months after first dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (patient wanted to receive second dose of primary series 6 months after first dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (patient wanted to receive second dose of primary series 6 months after first dose).    Concomitant medications details were not reported by the reporter.  Reportedly, Healthcare professional was not aware of any symptoms reported by patient after first dose.  Treatment details were not reported by the reporter.
Local rxn - erythema & swelling at injection site ((L) arm). Both resolved about 15 mins after 12.5mg of BENADRYL PO given.
Pruritic indurated plaque of approximately 4 x 7 cm of dusky erythematous hue (faint)